Phospholipase C δ-4 overexpression upregulates ErbB1/2 expression, Erk signaling pathway, and proliferation in MCF-7 cells by Leung, David W et al.
BioMed  Central
Page 1 of 15
(page number not for citation purposes)
Molecular Cancer
Open Access Research
Phospholipase C δ-4 overexpression upregulates ErbB1/2 
expression, Erk signaling pathway, and proliferation in MCF-7 cells
David W Leung*, Chris Tompkins, Jim Brewer, Alexey Ball, Mike Coon, 
Valerie Morris, David Waggoner and Jack W Singer
Address: Cell Therapeutics, Inc., 201 Elliott Ave., W., Seattle, WA 98119, U.S.A
Email: David W Leung* - dwleung1@msn.com; Chris Tompkins - ctompkins@acceleratorcorp.com; Jim Brewer - jbrewer@dynamac.com; 
Alexey Ball - aball@ctiseattle.com; Mike Coon - mcoon@ctiseattle.com; Valerie Morris - valmorr@yahoo.com; 
David Waggoner - wags@u.washington.edu; Jack W Singer - jsinger@ctiseattle.com
* Corresponding author    
Abstract
Background:  The expression of the rodent phosphoinositide-specific phospholipase C δ-4
(PLCδ4) has been found to be elevated upon mitogenic stimulation and expression analysis have
linked the upregulation of PLCδ4 expression with rapid proliferation in certain rat transformed cell
lines. The human homologue of PLCδ4 has not been extensively characterized. Accordingly, we
investigate the effects of overexpression of human PLCδ4 on cell signaling and proliferation in this
study.
Results: The cDNA for human PLCδ4 has been isolated and expressed ectopically in breast cancer
MCF-7 cells. Overexpression of PLCδ4 selectively activates protein kinase C-φ and upregulates the
expression of epidermal growth factor receptors EGFR/erbB1 and HER2/erbB2, leading to
constitutive activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) pathway in MCF-
7 cells. MCF-7 cells stably expressing PLCδ4 demonstrates several phenotypes of transformation,
such as rapid proliferation in low serum, formation of colonies in soft agar, and capacity to form
densely packed spheroids in low-attachment plates. The growth signaling responses induced by
PLCδ4 are not reversible by siRNA.
Conclusion: Overexpression or dysregulated expression of PLCδ4 may initiate oncogenesis in
certain tissues through upregulation of ErbB expression and activation of ERK pathway. Since the
growth responses induced by PLCδ4 are not reversible, PLCδ4 itself is not a suitable drug target,
but enzymes in pathways activated by PLCδ4 are potential therapeutic targets for oncogenic
intervention.
Background
Phosphoinositide-specific phospholipase C (PI-PLC)
plays a role in the inositol phospholipid signaling by
hydrolyzing phosphatidylinositol-4,5-bisphosphate
(PIP2). This reaction produces two intracellular second
messengers, inositol 1,4,5-trisphosphate (IP3) and dia-
cylglycerol (DAG), which cause the increase of intracellu-
lar calcium concentration and the activation of protein
kinase C (PKC), respectively [1-3]. In addition to hydro-
lyzing PIP2, PI-PLC can also utilize phosphatidylinositol
(PI) or PI-4-phosphate as substrates.
Published: 13 May 2004
Molecular Cancer 2004, 3:15
Received: 31 December 2003
Accepted: 13 May 2004
This article is available from: http://www.molecular-cancer.com/content/3/1/15
© 2004 Leung et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/15
Page 2 of 15
(page number not for citation purposes)
The PLC family in murine or human species is comprised
of 11 subtypes. On the basis of their structure, they have
been divided into four classes, β (β1, 2, 3 and 4), γ (γ1 and
2), δ (δ1, 3 and 4), ε, and ζ types. Positive regulation
mechanisms of PLC by association with membrane recep-
tors are well characterized in β- and γ-type isozymes [2]. β-
type isozymes are activated by the Gα  or Gβγ  subunit
released from heterotrimeric Gαβγ proteins after ligand
stimulation. γ-type isozymes are activated by the phos-
phorylation of specific tyrosine residues through the acti-
vation of receptor or nonreceptor tyrosine kinases. ε-type
enzymes possess both PLC and ras dependent guanine
nucleotide exchange (RasGEF) activity. As such, PLCε may
mediate the effects of G protein-coupled receptors
through two divergent pathways involving PI hydrolysis
as well as direct activation of the Ras/MAP kinase pathway
[4-6]. PLCζ, a sperm protein that shows similarity to a
truncated PLCδ with the pleckstrin homology (PH)
domain deleted, is involved in the triggering of Ca++ oscil-
lations in eggs [7]; however, it remains to be documented
whether PLCζ does have PLC enzymatic activity.
The regulation of δ-type PLC activity is less understood;
however, certain isoforms of δ-type PLC such as δ1 can be
regulated through interaction with a dual function G-pro-
tein (Gh) that also has transglutaminase activity [8,9].
Another δ-type PLC isozyme known as PLCδ4 has been
implicated to have a key role in cell proliferation, as its
mRNA is expressed in higher levels in regenerating liver
than in normal resting liver and in tumor cells such as
hepatoma and src-transformed cells than in non-trans-
formed cells. Western blot analysis and immunohisto-
chemical staining showed that the murine PLCδ4 is
predominantly present in nuclei with its expression level
markedly induced by serum in serum-starved murine
cells, whereas the amounts of PLCβ1, PLCγ1, and PLCδ1
do not change significantly after serum stimulation [10].
The rat PLCδ4 level has also been found to be markedly
elevated in a fast proliferating hepatoma H3924A cell line
comparing to a slow growing hepatoma H7795 line; how-
ever, immunohistochemical staining and western analysis
of subcellular fractions show rat PLCδ4 is mainly
expressed in the cytoplasmic fraction [11]. These results
suggest that PLCδ4 is expressed in response to mitogenic
stimulation and plays important roles in cell growth and
tumorigenesis. Splice variants of rat PLCδ4 with enzy-
matic PLC activities or with dominant-negative activity
[12,13], and the promoter region of murine PLCδ4 [14]
have also been described. Gene knockout by homologous
recombination shows PLCδ4-/- sperms are not able to ini-
tiate the acrosome reaction required for egg fertilization
[15].
Despite the extensive characterization of the murine or rat
PLCδ4 enzyme, the effect of overexpression of the human
form of PLCδ4 in cells has not been characterized. This
paper reports the molecular cloning of human PLCδ4 and
examines the signaling pathways that are affected by
ectopic expression of PLCδ4 in human breast cancer MCF-
7 cells.
Results
Human PLCδ4 expression in normal and tumor tissues
Based on sequence homology with the rat PLCδ4, we have
assembled a full-length cDNA for human PLCδ4. More
recent search of the Genbank database showed the coding
region of our human PLCδ4 cDNA matches 100% with an
annotated protein product from the Mammalian Gene
Collection (GenBank# BC006355), suggesting no PCR
errors were introduced during the assembly of our full
length clone. Alignment of the PLCδ4 cDNA sequence
with human genome http://genome.ucsc.edu/cgi-bin/
hgGateway shows PLCδ4 gene to be located at chromo-
some 2q35 and contains 16 exons that span about 30 kbp.
In addition to the full length PLCδ4 clone, a splice variant
of PLCδ4, PLCδ4b, with exons 7, 8, and 9 deleted was iso-
lated, resulting in the introduction of a premature stop
codon after amino acid residue 274. Scanning of protein
motifs [16] within the human PLCδ4 coding sequence
identified a pleckstrin homology (PH) domain, EF-hand
domains, PI-PLC-X and PI-PLC-Y catalytic domains, and a
C2 domain that are commonly found in PLCδ proteins,
whereas PLCδ4b contains only the coding regions for the
PH and EF-hand domains (Figure 1). Northern blot anal-
ysis of normal tissues using human PLCδ4 cDNA as a
probe shows PLCδ4 is most highly expressed in skeletal
muscle and kidney tissues, and at moderate level in intes-
tinal tissue (Figure 1, lower left panel). To assess the rela-
tive abundance of full length PLCδ4 and splice variant
PLCδ4b, primers located upstream and downstream of
the coding region for exons 7, 8, and 9 were used to detect
PCR products generated from cDNA samples derived from
various normal human tissues. For all tissues where full
length PLCδ4 (800 bp product) can be detected, the splice
variant PLCδ4b (300 bp product) can also be detected
readily (Figure 1, lower right panel). To test whether
PLCδ4 may be differentially expressed in certain normal
vs tumor cells, we examined the expression of PLCδ4
using Cancer Profiling Arrays (BD Clontech, Palo Alto,
CA) that contain hundreds of genetically matched cDNA
pairs isolated from tumor and normal tissue samples (Fig-
ure 2). Consistent with data from Northern analysis, nor-
mal tissues from kidneys show the highest expression of
PLCδ4, and the moderate expression of PLCδ4 in normal
intestinal tissues can also be extended to stomach, colon,
and rectal tissues from the rest of the alimentary tract.
PLCδ4 expression is found to be downregulated in a high
percentage of these tumor tissues as well as in prostate,
vulva, thyroid, skin, and pancreatic tissues, whereas
PLCδ4 expression is found to be upregulated in a highMolecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/15
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percentage (>25%) of breast and testicular tumor tissues
and in a low percentage (<5%) of lung and uterine tumor
tissues, when compared to the corresponding normal
tissues.
Generation of human PLCδ4 overexpressing MCF-7 cells
Since profiling of tissue arrays showed PLCδ4 to be over-
expressed in breast tumor tissues (Figure 2), PLCδ4 was
ectopically expressed in a breast cancer cell line of low
tumorigenicity, MCF-7, to study whether PLCδ4 overex-
pression would affect any transformation phenotypes of
the cells. When using PIP2 (Figure 3, panel A) as the sub-
strate, PLCδ4 overexpressing clones in MCF-7 cell extracts
show about 3 to 5 fold increase in PLC activity when com-
pared to cells (~25 nmol/min/mg) transfected with a con-
trol vector expressing EGFP (Clonetech, Palo Alto, CA);
whereas with PI as the substrate, PLCδ4a overexpressing
c l o n e s  ( F i g u r e  3 ,  p a n e l  B )  s h o w  a b o u t  2 0  t o  5 0  f o l d
increase in PLC activity when compared to untransfected
MCF-7 cells (~6 nmol/min/mg) or cells transfected with a
control vector. These results show the human PLCδ4
cDNA isolated does encode an active enzyme with PLC
activity. The more substantial increase in activity when
using PI as opposed to using PIP2 as the substrate may be
due to the preference of human PLCδ4 for PI over PIP2
and/or the preference of the endogenous PLC isoforms
present in MCF-7 for PIP2 over PI. Similar to other PLCs,
PLCδ4 can therefore use both PI and PIP2 as substrates,
Linear map of hPLCδ4 isoforms and expression in normal tissues Figure 1
Linear map of hPLCδ4 isoforms and expression in normal tissues. The top panel depicts linear map of the full length 
and an alternatively spliced form of hPLCδ4 proteins. The dotted line refers to exons deleted, the triangle refers to intron 
inserted, and the stop signs refer to premature stop codons introduced as a result of alternative splicing. The lower panels 
show Northern blot (left panel) and PCR analysis (right panel) of PLCδ4 expression in various normal tissues.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/15
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although the preference for PIP2 to PI may vary from one
PLC isoforms to another [17].
Since the murine PLCδ4 has been found to be expressed
predominantly in nuclei [10], nuclear fraction from a
PLCδ4 overexpressing clone (Sample#2, Figure 3, panel B)
was prepared to examine the distribution of PLC activity
in nuclear vs whole cell extracts. The nuclear extract was
found to contain about 1/3 of the total PLC activity when
compared to whole cell extract, suggesting that, unlike
murine PLCδ4 [10] but similar to rat PLCδ4 [11], human
PLCδ4 is mainly found in cytoplasmic fractions. The struc-
ture of the PH domain is the major factor that determines
the subcellular localization of PLC [18,19]. Consistent
with cytoplasmic location based on cell fractionation
data, fusion protein with green fluorescent protein (GFP)
linked to the PH domain of PLCδ4 overexpressed in cells
are associated with cytoplasmic membrane structures
(Figure 3, panel C). GFP fusion constructs for PH domain
of PLCβ1 have also been found in cytoplasmic mem-
branes [19], whereas that of PLCδ1 have been found
mainly in plasma membranes [18]. Including conserva-
tive amino acid changes, the matches between the PH
domains of PLCδ1 and PLCδ4 exceed 80%, suggesting
subtle changes in the PH domain can affect protein
localization.
PLCδ4 selectively activates protein kinase C-φ in MCF-7 
cells
Since DAG is a key lipid second messenger generated from
hydrolysis of PI or PIP2 by PLC and protein kinase C
(PKC) is the major family of proteins that are activated by
Cancer Profiling Array analysis of PLCδ4 expression using genetically matched cDNA pairs derived from tumor and normal tis- sue samples Figure 2
Cancer Profiling Array analysis of PLCδ4 expression using genetically matched cDNA pairs derived from 
tumor and normal tissue samples. Nylon membranes containing cDNA samples derived from various matched tumor and 
normal tissues on Cancer Profiling Array I and II (Clontech, Palo Alto, CA) were hybridized in ULTRAhyb™ (Ambion, Austin, 
TX) with a 2000 bp PLCδ4 coding fragment labeled with [α-32P]dCTP using a Strip-Ez labeling kit (Ambion, Austin, TX). 
Detailed description of each sample in Cancer Profiling Array I (left panel) and Cancer Profiling Array II (right panel) can be 
found at http://www.bdbiosciences.com/clontech/products/families/Disease_Profiling/index.shtml.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/15
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DAG, we examined whether PLCδ4 overexpression would
lead to activation of PKCs in MCF-7 cells. Analysis of PKC
activation (Figure 4, left panel) using a phospho-PKC
(pan) antibody that can detect PKCα, βI, βII, δ, ε, or η iso-
forms when a serine near the carboxy-terminus is auto-
phosphorylated showed some or all of these PKC
isoforms were already activated in cells transfected with
control vector, pCivirPu, and no enhancement of overall
phosphorylation was detected in cells overexpressing
PLCδ4. Similarly, no enhancement of PKC phosphoryla-
tion was observed using an antibody specific for the detec-
tion of the subset of PKCα or PKCβII when thr638 or
thr641 was phosphorylated respectively. On the contrary,
PKCφ was activated in all four independent isolated lines
of PLCδ4 overexpressing cells, whereas no phosphoryla-
tion was detected in vector control cells using an antibody
PLC assays in PLCδ4 overexpressing cells and expression of GFP-PH domain/PLCδ4 fusion protein in MCF-7 cells Figure 3
PLC assays in PLCδ4 overexpressing cells and expression of GFP-PH domain/PLCδ4 fusion protein in MCF-7 
cells. Assay of enzymatic activities of PLCδ4 overexpressing clones in MCF-7 cell extracts were carried out using PIP2 (panel 
A) or PI (panel B) as the substrate. EGFP refers to cells transfected with a control vector expressing EGFP (Clonetech, Palo 
Alto, CA); MCF-7 refers to untransfected cells; #1, 2, 4, 5, 10, and 11 refer to activities derived from total cell extracts of inde-
pendent isolates of PLCδ4 overexpressing clones. #2 nuclei refers to activities derived from nuclear extracts of PLCδ4 overex-
pressing clone #2. Assays were done in triplicates with error bars indicating ± standard deviation (SD). Fusion protein 
comprised of the PH domain of PLCδ4 and GFP was localized mainly in the cytoplasmic region (panel C).Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/15
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specific for the detection of the PKCφ when thr538 was
phosphorylated. No consistent change in phosphoryla-
tion trend was seen between PLCδ4 overexpressing cells
and control cells when using an antibody specific for the
detection of the subset of PKCζ or PKCλ when thr410 or
thr403 was phosphorylated respectively, suggesting that
the two outliers, one in the PLCδ4 overexpressing samples
and one in the vector samples, may represent clonal vari-
ations. Hence PKCφ is the isoform of PKC that shows sig-
nificant accentuation of activation in PLCδ4
overexpressing MCF-7 cells. Another method to assess
PKC activation is to follow the phosphorylation of serine
in PKC substrates using an antibody specific for the con-
sensus motif of PKC substrates that detects phosphor-
ylated serineresidues when surroundedby Arg or Lys at the
-2 and +2 positions anda hydrophobic residue at the +1
position in proteins. Samples from MCF-7 transfected
with vector controls (Figure 4, right panel) showed two
major phosphorylated bands, whereas PLCδ4 overex-
pressing cells showed a few additional weak phosphor-
ylated bands, consistent with the data that only a limited
subset of PKCs are activated with PLCδ4 overexpression.
Constitutive activation of extracellular signal-regulated 
kinase (ERK) pathway in PLCδ4 overexpressing cells
To determine whether PLCδ4 overexpression and/or
PKCφ activation would affect signal transdutions path-
ways essential for cell proliferation in MCF-7 cells, phos-
pho-specific antibodies against various key kinases were
used to assess the activation of multiple pathways. Analy-
sis of Erk1/2 or p44/42 MAPK activation (Figure 5) using
an antibody specific for dually phosphorylated Erk1/2 at
Thr202 and Tyr204 showed Erk1/2 was activated in all
four independent isolated lines of PLCδ4 overexpressing
cells, whereas little phosphorylation was detected in vec-
tor control cells. The increase in activated Erk1/2 in PLCδ4
overexpressing cells is due to modifications in protein
phosphorylation rather than to change in Erk1/2 proteins
level, as similar levels of expression were found using an
antibody for the detection of total levels of endogenous
Overexpression of PLCδ4 selectively activates PKC-φ in MCF-7 cells Figure 4
Overexpression of PLCδ4 selectively activates PKC-φ in MCF-7 cells. Western blot analysis of MCF-7 cell extracts 
derived from independent isolates overexpressing PLCδ4 and isolates transfected with control vectors using antibodies against 
various isoforms of phospho-PKC (left panel) and against the phosphorylated motif of PKC substrates (right panel). Antibodies 
were from Cell Signaling Technology (Beverly, MA). Blotting was done using the ECL Plus™ detection reagents from Amer-
sham Biosciences (Piscataway, NJ).Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/15
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Erk1/2 proteins in all samples. Similarly, kinases
upstream of the Erk signaling pathway such as MAPK or
Erk kinases (MEK1/2) as well as downstream of the Erk
pathway such as such as the 90 kDa ribosomal S6 kinase
(p90RSK) were also activated in PLCδ4 overexpressing
cells based on western blot analysis with antibodies spe-
cific for MEK1/2 when phosphorylated at Ser217/221 and
for p90RSK when phosphorylated at Thr359/Ser363. On
the contrary, key proteins, such as stress activated protein
kinase (SAPK) or Jun-N-terminal kinase (JNK), the 38 kDa
mitogen activated kinase (p38 MAPK), and Akt or protein
kinase B, involved in two alternative mitogen activated
protein kinases (MAPK) pathways and the phosphoi-
nositide-3-phosphate kinase (PI3K) pathway, respec-
tively, showed no change in activation in PLCδ4
overexpressing cells based on western blot analysis with
antibodies specific for p46 and 54 SAPK when dually
phosphorylated at Thr183/Tyr185, for p38 MAPK when
dually phosphorylated at Thr180/Tyr182, and for Akt
when phosphorylated at Ser473. Hence PLCδ4 overex-
pression selectively activates the Erk or the p44/42 MAPK
pathway constitutively with minimal effects on the SAPK/
JNK, the p38 MAPK, and the PI3K pathways.
Upregulation of EGFR/ErbB1 and HER2/ErbB2 in PLCδ4 
overexpressing cells
In breast cancer, the hyperactivation of the Erk pathway is
often associated with the upregulation of EGFR expression
and the downregulation of estrogen receptor (ERα)
expression [20,21]. Accordingly, we examined the expres-
sion levels of EGFR and ERα in PLCδ4 overexpressing
MCF-7 cells. Analysis of ERα expression and ERα activa-
tion (Figure 6) using an antibody specific for ERα protein
and an antibody specific for ERα phosphorylated at
Ser167 showed no significant differences between PLCδ4
overexpressing cells and vector control cells after adjusting
for samples loading differences using the amount of heat
shock protein 90 (Hsp90) detected as loading controls.
On the contrary, analysis of EGFR/erbB1 total protein
level or EGFR activation using antibodies specific for
EGFR protein or for EGFR phosphorylated at Tyr992 and/
or Tyr1068 showed both EGFR overall protein level and
the phosphorylated forms of EGFR were substantially ele-
vated in all four independent isolated lines of PLCδ4 over-
expressing cells, whereas little EGFR and phosphorylated
EGFR were detected in all five independent isolated lines
of vector control cells and in untransfected MCF-7 cells. As
similar extents of elevation were found for both EGFR and
the phosphorylated forms of EGFR, it is likely that PLCδ4
overexpression upregulates EGFR at the genomic or at the
Overexpression of PLCδ4 activates Erk1/2 pathway in MCF- 7 cells Figure 5
Overexpression of PLCδ4 activates Erk1/2 pathway 
in MCF-7 cells. Western blot analysis of MCF-7 cell 
extracts derived from 4 independent isolates overexpressing 
PLCδ4 (left 4 lanes) and 2 isolates transfected with control 
vectors (right 2 lanes) using antibodies against various phos-
phorylated forms of kinases and non-phosphorylated Erk1/2. 
Antibodies were from Cell Signaling Technology (Beverly, 
MA). Blotting was done using the ECL Plus™ detection rea-
gents from Amersham Biosciences (Piscataway, NJ).
Overexpression of PLCδ4 upregulates ErbB1/2 but does not  affect ER-α in MCF-7 cells Figure 6
Overexpression of PLCδ4 upregulates ErbB1/2 but 
does not affect ER-α in MCF-7 cells. Western blot analy-
sis of MCF-7 cell extracts derived from 2 untransfected sam-
ples (left 2 lanes), 4 independent isolates overexpressing 
PLCδ4 and 5 isolates transfected with control vectors (right 
5 lanes) using antibodies against Hsp90 (Biosource Interna-
tional, Camarillo, CA), various non-phosphorylated and 
phosphorylated forms of ER-α and EGFR (Cell Signaling 
Technology, Beverly, MA), and non-phosphorylated ErbB2 
(Upstate Cell Signaling Solutions, Charlottsville, VA). Blotting 
was done using the ECL Plus™ detection reagents from 
Amersham Biosciences (Piscataway, NJ).Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/15
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transcriptional level rather than at the post-translational
modification level.
EGFR can also form heterodimers with other members of
erbB receptors such as the ligand-less erbB2 to promote
tumor progression [22]. ErbB2/HER2 is overexpressed in
20%–30% of breast and ovarian cancer patients and is
associated with aggressive tumor characteristics and poor
prognosis. Analysis of erbB2 total protein level with anti-
erbB2 showed erbB2 protein levels were also elevated in
all four independent isolated lines of PLCδ4 overexpress-
ing cells, whereas little ErbB2 was detected in all five inde-
pendent isolated lines of vector control cells and in
untransfected MCF-7 cells.
PLCδ4 overexpression enhances MCF-7 cells proliferation 
in low serum, colonies formation in soft agar, and spheroid 
density on hydrogel
To assess whether PLCδ4 overexpression in cells would
lead to certain phenotypic changes that are commonly
observed in transformed cells, the growth characteristics
in low serum (0.5%) of MCF-7 cell lines overexpressing
PLCδ4 and of lines transfected with vector control were
compared. All three independent lines of MCF-7 cells
carrying the vector overexpressing PLCδ4 have a higher
proliferation rate than that of the parental MCF-7 cell line
and those of the three vector control lines (Figure 7),
despite any apparent growth disadvantage of cells carrying
the control vector when compared to untransfected cells.
Another common division abnormality of cancer cells is
their capacity to grow with less anchorage dependency
and to divide when held in suspension without attach-
ment or with minimal attachment to a rigid surface. This
can either be assayed by the propensity of a given cell line
to form colonies in soft agar or to form dangling sphe-
roids on top of Costar® Ultra-Low Attachment Clusters
plate surface made up of a neutrally charged hydrogel
layer, as the presence of soft agar or hydrogel at the bot-
tom of the culture dish eliminates or minimizes cell con-
tact with the tissue culture plate surface conducive for cell
attachment. MCF-7 cells overexpressing PLCδ4 can form
colonies in soft agar (21 ± 3 colonies at an initial plating
density of 105 cells/ml), whereas cells transfected with the
control vector do not form colonies when seeded at
similar densities (Figure 8). Although untransfected MCF-
7 cells, vector control cells, and PLCδ4 overexpressing
cells can all form dangling spheroids on hydrogel layers,
the spheroids from PLCδ4 overexpressing cells appear to
be more densely packed as evidenced by their more
opaque structure under the light microscope (Figure 9).
These data suggest that PLCδ4 overexpression may con-
tribute to a transformation phenotype by promoting both
anchorage dependent and independent cell growth.
The induction of growth signaling response is not reversible 
by siRNA specific for PLCδ4
To test whether PLCδ4 is a druggable cancer target of
which its effects on growth signaling can be reversed by a
specific inhibitor for PLCδ4, we introduced siRNA into a
cell line (PLCδ4-16) overexpressing PLCδ4 to see if there
is any attenuation of signal responses. Western blottings
show the expression levels of PLCδ4 in the lysates of over-
expressing cells were reduced almost down to those of
vector control cells using any three of the siRNAs specific
for PLCδ4 (Figure 10, δ4.1, 2 or 3), whereas scrambled
siRNA or siRNA specific for lamin A/C had no effect on
PLCδ4 level. As expected, siRNAs for PLCδ4 had little
effect on total Erk1/2 and Hsp90 level and siRNA for
Lamin A/C knocked down only the level of Lamin C.
Unexpectedly,  β-actin and Lamin C were elevated in
PLCδ4 overexpressing cells compared to vector control
cells. Although frequently regarded as a housekeeping
gene or an innocuous gene for siRNA control, respectively,
β-actin and Lamin C can be upregulated in certain rapidly
proliferating cells [23,24]. As determined previously, both
ErbB1 expression level and Erk1/2 phosphorylation were
elevated in PLCδ4 overexpressing cells compared to vector
control cells; however, no reduction in these two growth
signaling responses could be detected in the presence of
PLCδ4 siRNAs despite >80% knockdown of PLCδ4
expression. Hence it is not possible to reverse the transfor-
mation phenotype induced by PLCδ4 using siRNA.
PLCδ4 overexpressing cells enhance cell proliferation in low  (0.5%) serum Figure 7
PLCδ4 overexpressing cells enhance cell proliferation 
in low (0.5%) serum. 3 independent isolates overexpress-
ing PLCδ4 were designated as δ4.14, δ4.15, and δ4.16; 3 iso-
lates transfected with control vectors as vect.2, vect.4, and 
vect.5; and untransfected cells as MCF-7. Cell proliferation 
assays were performed using the CellTiter 96® AQueous One 
Solution (Promega, Madison, WI) in triplicates with error 
bars indicating ± SD.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/15
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Discussion
The expression of the rodent phosphoinositide-specific
phospholipase C δ-4 (PLCδ4) has been found to be
elevated upon serum stimulation in Swiss 3T3 cells and
Northern blot analysis have linked the upregulation of
PLCδ4 expression with rapid proliferation in hepatocytes
and with oncogenic transformation in certain rodent cell
lines [10], suggesting that PLCδ4 may be an enzyme target
for oncogenic intervention. Accordingly, we have isolated
the cDNA for human PLCδ4 to probe the expression of
PLCδ4 using northern blot and cDNA expression panel
derived from normal tissues (Figure 1) and Cancer
Profiling Arrays (BD Clontech, Palo Alto, CA) derived
from genetically matched cDNA pairs isolated from vari-
ous tumor and normal tissue samples (Figure 2). The
truncated splice variant of PLCδ4, PLCδ4b, was found to
expressed in the same tissues where full length PLCδ4
could be detected (Figure 1, lower right panel), consistent
with the recent discovery of widespread use of a mecha-
nism that coupled alternative splicing with a premature
stop codon for the downregulation of a transcript through
nonsense-mediated mRNA decay [25]. A somewhat anal-
ogous splice variant with premature stop codon has been
isolated for rat PLCδ4 with dominant-negative activity
[13]; however, coexpression of human PLCδ4 along with
PLCδ4b has not led to significant reduction of PLC activity
in MCF-7 cells in our hands (data not shown) possibly
due to subtle differences between the human and the rat
sequences. Though PLCδ4 expression was found to be
downregulated in the majority of tumor tissues, it was
found to be upregulated in a high percentage (>25%) of
breast and testicular tumor tissues. The overexpression of
PLCδ4 in testicular tumor is of interest, as the only
observed phenotype in PLCδ4-/- mice is having defective
PLCδ4 overexpressing cells form colonies in soft agar Figure 8
PLCδ4 overexpressing cells form colonies in soft agar. The cells were plated at 1 × 105 cells/ml in 6-well plates contain-
ing RPMI 1640 with 0.35% agar, 5% FBS, 10% tryptose phosphate broth, 100 nM 17-β-estradiol. The picture was taken on day 
10 with 40× magnification. Samples were plated on duplicate wells. The two numbers separated by a slash mark shown at the 
lower right-hand corner of each panel represent the total number of colonies scored in each of the two wells.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/15
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sperms [15], suggesting PLCδ4 plays an important role in
testis and that deregulation of PLCδ4 expression in testis
can lead to oncogenesis. With the exceptions of a few uni-
versal tumor antigens such as telomerase, survivin,
mdm2, cytochrome P450 1B1 [26] and sphingosine
kinase 1 [27] that are overexpressed in most tumor tissues,
the differential overexpression of PLCδ4 in selected tumor
tissues is consistent with the expression pattern of most
individual oncogenes, where overexpression is only found
in restricted tissues as opposed to all tumor tissues,
despite the fact that various tumor tissues do share a com-
mon cluster of overexpressed genes related to cell cycling
and DNA replication [28]. Hence experiments in addition
to expression profiling are required to determine whether
PLCδ4 is a gene with oncogenic potential.
We have studied the effects of overexpression of human
PLCδ4 on cell signaling and proliferation in this study.
MCF-7, a breast cancer cell line of low tumorigenicity, was
chosen for ectopic expression of PLCδ4, since profiling of
tissue arrays showed PLCδ4 can be overexpressed in breast
tumor tissues (Figure 2). Constitutive overexpression of
PLCδ4 selectively activates protein kinase C-φ (Figure 4,
left panel), whereas the activation states of all other iso-
forms of PKC studied are not affected by PLCδ4 overex-
pression based on using phospho-specific PKC isoform-
specific antibodies. The data is consistent with results
from another phospho-specific antibody against the con-
sensus motif of PKC substrates, showing slight enhance-
ment of phosphorylation of PKC substrates with PLCδ4
overexpression (Figure 4, right panel).
PLCδ4 overexpressing cells form more densely packed spheroids Figure 9
PLCδ4 overexpressing cells form more densely packed spheroids. Cells were grown in Costar® Ultra-Low Attach-
ment Clusters Plates (Corning, Acton, MA) in RPMI supplemented with 10% FBS. The pictures were taken on day 5 with 40× 
magnification.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/15
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Using antibodies that target signaling pathways for cell
proliferation, we have found that PLCδ4 overexpression
leads to constitutive activation of extracellular signal-reg-
ulated kinases 1 and 2 (ERK1/2) pathway in MCF-7 cells
(Figure 5) and of kinases both upstream and downstream
of the Erk signaling pathway such as Erk kinases (MEK1/
2) and the 90 kDa ribosomal S6 kinase (p90RSK),
whereas key proteins involved in two alternative MAPK
pathways and the PI3K pathway, such as SAPK/JNK, p38
MAPK, and Akt, respectively, showed no change in activa-
tion in PLCδ4 overexpressing cells. PLCδ4 overexpression
also upregulates the expression of epidermal growth fac-
tor receptors EGFR/erbB1 and HER2/erbB2 in MCF-7 cells
(Figure 6). Of the four ErbB isoforms, cells co-expressing
ErbB1 and ErbB2 have been found to be the most aggres-
sive in forming tumors in mice [29]. Though upregulation
of EGFR expression is often associated with the downreg-
ulation of estrogen receptor (ERα) expression in breast
cancer cells [20,21], no significant change was found in
ERα expression in PLCδ4 overexpressing MCF-7 cells
(Figure 6). Since both EGFR transcription [21,30] and
ErbB2 expression [31] have been found to be upregulated
by phorbol ester, it is possible that the DAG generated
from PLCδ4 overexpression may activate selective PKCs
such as PKC-φ, leading to enhancement of EGFR and
ErbB2 gene transcription and activation of the Erk signal-
ing pathway.
We have examined several cell growth parameters to
determine whether enhancement of ErbB1/2 expression
and activation of Erk pathway in PLCδ4 overexpressing
MCF-7 cells can be translated into a more proliferative
state of cell growth. MCF-7 cells stably expressing PLCδ4
demonstrate several phenotypes of transformation;
namely, enhanced rate of proliferation and saturating cell
density in low serum (Figure 7), improved efficiency in
forming colonies in soft agar (Figure 8), and capacity to
form more densely packed spheroids in low-attachment
plates (Figure 9). These data suggest that PLCδ4 overex-
pression may contribute to a transformation phenotype
by promoting both anchorage dependent and independ-
ent cell growth.
A criterion for validation and selection of new drug targets
is to determine whether there is evidence of the reversal of
the transformation phenotype using genetic means or
drug leads. We have been able to knock down the expres-
sion of PLCδ4 in PLCδ4 overexpressing cells by transfect-
ing siRNAs specific for PLCδ4 sequences (Figure 10);
however, no reduction in ErbB1 expression level and
Erk1/2 phosphorylation in PLCδ4 overexpressing cells in
the presence of siRNA could be detected. The growth sig-
naling responses induced by PLCδ4 are hence not reversi-
ble by siRNA. The inability for siRNAs for PLCδ4 to knock
down growth signaling responses suggests PLCδ4 may
play a role in the initiation of carcinogenesis by inducing
other genetic changes, as a neoplastic state can sometimes
be irreversible by becoming independent of the initiating
oncogenic event through induction of genome destabili-
zation. For instance, even transient induction of MYC
activity was able to sustain tumorigenesis in certain cell
PLCδ4 siRNAs knock down PLCδ4 expression but do not  affect the upregulation of EGFR and the activation of Erk1/2 Figure 10
PLCδ4 siRNAs knock down PLCδ4 expression but do 
not affect the upregulation of EGFR and the activa-
tion of Erk1/2. SiRNAs against varaious targets were 
obtained from Dharmacon Research (Lafayette, CO). See 
Methods section for sequence specifics and siRNA transfec-
tion procedure. Anti-PLCδ4 polyclonal antibodies raised in 
rabbits immunized with a synthetic peptide WEQQQT-
MARHLTEI corresponding to amino acids 390–402 of human 
PLCδ4 were obtained from Covance Research Products 
(Berkeley, CA). Antibodies against phosphorylated and non-
phosphorylated Erk1/2, EGFR, and Lamin A/C were from 
Cell Signaling Technology (Beverly, MA). Hsp90 antibodies 
were from Biosource International (Camarillo, CA). β-actin 
antibodies were from Santa Cruz Biotechnology (Santa Cruz, 
CA). Western blot analyses were performed using the ECL 
Plus™ detection reagents from Amersham Biosciences (Pis-
cataway, NJ).Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/15
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types [32]. Overexpression of ErbB2, a receptor induced
by PLCδ4 (Figure 6), has also been associated with genetic
instability in cells [33]. These results suggest that PLCδ4
per se may be a difficult target to be manipulated with
drugs, and the sites for intervention may lie instead on
other enzyme targets in pathways activated by PLCδ4,
such as the ErbB receptors and the Ras/Raf/MAP kinase
cascade. The validation of some these targets has been
confirmed with two approved drugs, Herceptin® specific
for ErbB2 and Iressa®  for EGFR tyrosine kinase, with
numerous inhibitors for the ErbB receptor family in
clinical trials [34], and with the studies of Raf inhibitor
BAY 37-9751 and MEK inhibitor CI-1040 along the ERK
pathway in clinical trials [35].
As activation of ErbB can activate another isoform of PLC,
PLCγ [2], it is also possible that activation PLCγ may com-
pensate for the knockdown of PLCδ4 by siRNA and that
compounds capable of inhibiting multiple isoforms of
PLC may be more suitable for oncogenic intervention. A
black-box approach can also be used to screen for com-
pounds by high throughput screening that would inhibit
growth signaling responses induced by PLCδ4 with differ-
ential cytotoxcity in PLCδ4 overexpressing MCF-7 cells
versus matched vector control cells. The use of human
engineered tumor cells has been successful in identifying
new as well as classical genotype-selective anti-tumor
compounds [36].
Conclusions
Overexpression or dysregulated expression of PLCδ4 may
initiate oncogenesis in certain tissues through upregula-
tion of ErbB expression and activation of ERK pathway.
PLCδ4 can therefore be a useful tumor marker for breast
or testicular cancer tissues. Since the growth signaling
responses induced by PLCδ4 are not reversible by siRNA,
a surrogate for a PLCδ4-specific inhibitor, PLCδ4 itself is
probably not a suitable drug target for development, but
enzymes in pathways activated by PLCδ4 are potential
therapeutic targets for oncogenic intervention. Alterna-
tively, a black-box approach can be used to screen com-
pounds with differential cytotoxcity in PLCδ4
overexpressing MCF-7 cells.
Methods
Isolation of human PLCδ4 cDNA
Search of the Genbank database [37] of expressed
sequence tag (dbEST) using the rat PLCδ4 protein
sequences [12] as probe identified an I.M.A.G.E. Consor-
tium [LLNL] cDNA clone (GenBank# AI366170), pBSK-
D4, isolated from a human oligodendroglioma library
containing an insert of ~2500 bp with three separate
stretches of sequences containing extensive homology to
the rat PLCδ4 coding sequence. These three coding
regions do not share a common reading frame and is most
likely derived from a spurious splice variant of human
PLCδ4 with exons deletion and intron insertion in two
separate areas. This cDNA clone thus codes for a truncated
PLCδ4 containing the first 258 amino acids of full-length
PLCδ4 with another 16 amino acids and a termination
codon added at the C-terminal end as a result of exons
deletion.
To isolate a human PLCδ4 cDNA encoding an active PLC
enzyme, PCR primers, oD4-2f, 5'-AGACACGTCC
CAGTCTGGAA CC-3', and oD4-2r, 5'-CTGCTTCCTC
TTCCTCATAT TC-3' (Qiagen, Alameda, CA) with
sequences, respectively, corresponding to the coding
strand upstream of a Eco RI site and to the complementary
strand downstream of a unique Hpa I site were used to
screen cDNAs derived from various human cell lines to
identify PCR products that are longer (due to insertion of
additional exons) than the product (expected to be ~300
bp) when using pBSK-D4 as the template. Templates from
cDNAs derived from CA-HPV-10, Capan-1, Hs.7661, Mia-
PaCa, A549, MDA-MB-231, Panc-1, NCI-H460, LnCaP,
MCF-7, and HNMEC cells all gave PCR products of ~800
bp upon amplification. The human normal mammary
epithelial cells (HNMEC) was fron Clonetics (Walkers-
ville, MD), whereas the rest of the cell lines were from
American Type Culture Collection (Manassas, VA). The
~800 bp PCR product was then cleaved with Eco RI and
Hpa I to generate a ~730 bp fragment for ligating into the
vector pBSK-D4 that had been cleaved with Eco RI and
Hpa I for the generation of the plasmid pBSK-D43X. DNA
sequence analysis shows the cDNA insert in pBSK-D43X
contains an additional ~500 bp region with extensive
homology to the rat PLCδ4 sequence not found within the
insert in pBSK-D4. pBSK-D43X lacked the 5'-end region of
PLCδ4 cDNA upstream of Ecor RI, as the ~840 bp Eco RI
fragment that spans the Eco RI site found in the 5'-cDNA
adaptor sequence and the internal Eco RI site found in the
PLCδ4 coding region was removed during preparation of
the Eco RI/Hpa I pBSK-D4 vector.
Separately, PCR primers with sequences corresponding to
the coding strand upstream of Hpa I of pBSK-D4, oD4-3f,
5'-CTGGTGAAGG GGAAGAAGTT A-3', and to the com-
plementary strand downstream of Bgl II, oD4-3r, 5'-
TGTCTAGACG AACGCCAAAG AT-3' were used to screen
cDNAs derived from human cell lines to identify PCR
products that are ~300 bp shorter (due to removal of a
putative intron sequence) than the product (~1050 bp)
when using pBSK-D4 as the template. A PCR product of
~700 bp was detected from cDNA template derived from
CA-HPV-10 cells. The ~700 bp PCR product was then
cleaved with Hpa I and Bgl II to generate a ~670 bp frag-
ment for ligating into the vector pBSK-D43X that had
been cleaved with Hpa I and Bgl II for the generation of
the plasmid pBSK-D43X1. DNA sequence analysis showsMolecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/15
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the cDNA insert in pBSK-D43X contains extensive homol-
ogy to the rat PLCδ4 sequence.
Construction of vectors for expression of human hPLCδ4 in 
mammalian cells
To assemble a full-length human PLCδ4a cDNA for
expression study, a ~600 bp Nhe I - Eco RI fragment was
isolated from digestion with Nhe I + Eco RI of the ~2200
bp PCR product generated by amplification from the tem-
plate pBSK-D4 using the primers oD4-1f, 5'-GTGATCT-
GGT GCTAGCTGGT GGAAC-3' and oD4-1r, 5'-
ACACCAATGC ATTCCCGTGA AATGCCCACC-3'; and a
~1700 bp Eco RI - Nsi I fragment isolated from digestion
with Eco RI + Nsi I of the ~1770 bp PCR product gener-
ated by amplification from the template pBSK-D43X1
using the primers oD4-2f and oD4-1r were combined and
inserted into the pCivIrPu vector that had been cleaved
with Nhe I and Nsi I via a three-part ligation for the gen-
eration of the plasmid pPuroD4F. pCivIrPu is derived
from the plasmids pIRESpuro (Clonetech, Palo Alto, CA)
and pCIneo (Promega, Madison, WI). Specifically, the
980 bp Spe I - Not I fragment from pCIneo was inserted
into the cloning vector pSL1180 (Amersham Pharmacia,
Piscataway, NJ) between the restriction sites Spe I and Not
I to generate pSLCI. The 1000 bp Spe I - Nsi I fragment
from pSLCI was then isolated for insertion into the vector
pIRESpuro between the restriction sites Spe I and Nsi I to
generate pCivIrPu.
To determine whether the human hPLCδ4a cDNA
sequence encodes a protein with phospholipase c (PLC)
activity, the plasmid pPuroD4F was stably transfected into
MCF-7 cells (American Type Culture Collection, Manas-
sas, VA) to generate puromycin-resistant clones. Specifi-
cally, pPuroD4F was digested with BspH I before
electroporating into these cell lines with a Cell-Porator™
(Life Technologies, Gaithersburg, MD) using conditions
described previously [38]. After adherence of the trans-
fected cells 48 hours later, the cells were grown in the
presence of 1.0 µg/ml puromycin to select for cells that
had incorporated the plasmid.
Construction of vectors for expression of GFP-PH/PLCδ4 
fusion proteins in mammalian cells
Coding region corresponding to the PH domain of PLCδ4
splice variant were amplified with PCR primers
oPHd4_1f, 5'-GCGCAGCGAA TTCATGGCGT CCCTGCT-
GCA AGAC-3' and o oPHd4_1r, 5'-GATCTAGTGT CGAC-
CCAAGA TCCACCAACA GCTGGAG-3' to generate a 400
bp fragment. The fragment was then cleaved with EcoR I
and Sal I to generate a 390 bp fragment for insertion
between the EcoR I and Sal I sites of pEGFP-n1 (Clontech,
Palo Alto, CA) for generation of pPHd4GFP, an
expression plasmid for fusion protein containing the PH
domain of PLCδ4 upstream of GFP.
Cell culture
Cell culture reagents were from Invitrogen (Carlsbad, CA).
Human tumor cell lines were from the American Type
Culture Collection (Manassas, VA). MCF-7, MCF-7 cells
stably overexpressing PLCδ4, or MCF-7 cells transfected
with control vector were grown in RPMI supplemented
with 10% FBS. Spheroids were grown on Costar® Ultra-
Low Cluster Plates (Corning, Acton, MA) in RPMI supple-
mented with 10% FBS. Cell proliferation assays were per-
formed using the CellTiter 96®  AQueous  One Solution
(Promega, Madison, WI). For colonies grow in soft agar,
cells in soft agar colony assay were cultured in 6-well
plates containing 104 or 105 cells/well in RPMI 1640 with
0.35% agar, 5% FBS, 10% tryptose phosphate broth, 100
nM 17-β-estradiol. The plates were incubated for 10 days,
after which the cultures were inspected and
photographed.
Antibodies
Phospho-PKC (pan), phospho-PKCα/βII (Thr638/641),
phospho-PKCφ (Thr538), phosphoPKCζ/λ (Thr410/
403), phospho-MEK1/2 (Ser217/221), phospho-Erk1/2
(Thr202/183+Tyr204/185), total Erk1/2, phospho-
p90RSK (Thr359+Ser363), phospho-SAPK p54/p46
(Thr183+Tyr185), phospho-p38 MAPK
(Thr180+Tyr182), phospho-Akt (Ser473), total ER-α,
phospho-ER-α (Ser167), total EGFR, phospho-EGFR
(Tyr992), phospho-EGFR (Tyr1068), phospho-(Ser) PKC
substrate and Lamin A/C antibodies were from Cell Sign-
aling Technology (Beverly, MA). Hsp90 antibodies were
from Biosource International (Camarillo, CA). HER-2
antibodies were from Upstate Cell Signaling Solutions
(Charlottsville, VA). β-actin antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA). Polyclonal anti-
bodies raised in rabbits immunized with a synthetic pep-
tide WEQQQTMARHLTEI corresponding to amino acids
390–402 of human PLCδ4 were obtained from Covance
Research Products (Berkeley, CA). Western blot analyses
were performed using the ECL Plus™ detection reagents
from Amersham Biosciences (Piscataway, NJ).
Assay of phospholipase C activity in PLCδ4 overexpressing 
cells
Puromycin-resistant clones were randomly selected to
check for PLC activity in cell extracts using a assay that
measures the conversion of radiolabeled PIP2 or PI to
DAG and IP3 or inositol-1-phosphate (Ins(1)P). To pre-
pare cell extracts for assay, cells from plates were scraped
into PBS + protease inhibitors. These cells were sonicated
3 times for 20 seconds using a probe sonicator. Protein
concentrations were determined and the lysates were used
for the assays. The assay of hydrolysis of PIP2 or PI was
based on methods described previously [39,40]. Specifi-
cally, each PI hydrolysis assay was in a total volumn of
200 µl composed of 250 µM PI (50 nmol), 20,000 cpmMolecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/15
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(0.030 µCi) of [3H]PI, 100 mM NaCl, 1 mM EGTA, 4 mM
CaCl2, 0.1 mM DTT, 50 mM HEPES buffer, pH 7.0, 1 mg/
ml sodium deoxycholate. A substrate solution enough for
50 assays was prepared by drying 5 ml of 500 µM PI + 1.5
µCi [3H]PI under N2 before resuspending in 5 ml of 2 mg/
ml sodium deoxycholate by sonication. A buffer solution
(10×) was made up of 250 mM HEPES pH 7.0, 1 M NaCl,
1 mM DTT. A Ca2+/EGTA solution (4×) was made up of 4
mM EGTA, 12 mM CaCl2, 100 mM HEPES pH 7.0 (free 3
mM Ca2+ in assay). After mixing 20 µl buffer solution, 50
µl Ca2+/EGTA, and 30 µl enzyme extract, the reaction was
started by addition of 100 µl substrate solution. After
incubating for 10 min at 37°C, the reaction was termi-
nated with 0.75 ml chloroform/methanol/HCl
(100:200:0.6, by volume), followed by 0.25 ml of chloro-
form (water saturated) and then 0.25 ml 1 N HCL con-
taining 5 mM EGTA. After centrifugation to separate the
phases, 300 µl of aqueous phase was then counted in scin-
tillation counter.
For the assay of PLC activity using PIP2 as the substrate,
each PI hydrolysis assay was in a total volumn of 200 µl
composed of 40 µM PI (8 nmol), 200 µM PE (40 nmol),
20,000 cpm (0.030 µCi) of [3H]PIP2, 3 mM MgCl2, 100
mM NaCl, 1 mM EGTA, 1 mM CaCl2 (free 45 µM Ca2+ in
assay), 0.1 mM DTT, 50 mM HEPES buffer, pH 7.0, 1 mg/
ml sodium deoxycholate. A substrate solution enough for
50 assays was prepared by drying 80 µM PIP2 (5 ml) + 400
µM PE + 1.5 µCi [3H]PIP2 under N2 before resuspending
in 5 ml of 65 mM HEPES pH 7.0, 100 mM NaCl, 2 mg/ml
sodium deoxycholate by sonication. A MgCl2 solution was
made up of 12 mM MgCl2, 50 mM HEPES pH 7.0, 200
mM NaCl, 0.4 mM DTT. A Ca2+/EGTA solution was made
up of 10 mM EGTA, 10 mM CaCl2, 50 mM HEPES pH 7.0.
After mixing 50 µl MgCl2 solution, 20 µl Ca2+/EGTA, and
30 µl enzyme extract, the reaction was started by addition
of 100 µl substrate solution. After incubating for 10 min
at 37°C, the reaction was terminated with 0.75 ml
chloroform/methanol/HCl (100:200:0.6, by volume),
followed by 0.25 ml of chloroform (water saturated) and
then 0.25 ml 1 N HCL containing 5 mM EGTA. After
centrifugation to separate phases, 300 µl of aqueous phase
was then counted in scintillation counter.
Preparation of nuclear extracts
MCF-7 cells were harvested with 0.2% trypsin and washed
two times with cold PBS. The cells were suspended in
buffer A (10 mM Tris/HCl, pH 7.8), 1% Nonidet P-40, 10
mM β-mercaptoethanol, 0.5 mM PMSF, 1 µg/ml apro-
tinin and leupeptin) for 2 min on ice. An equal volume of
distilled H2O was added, and the cells were allowed to
swell for 2 min. The cells were sheared by ten passages
through a 22-gauge needle. The nuclei were recovered by
centrifugation at 400 × g for 6 min and washed once with
buffer B (10 mM Tris/HCl (pH 7.4), 2 mM MgCl2, 0.5 mM
PMSF, 1 µg/ml aprotinin and leupeptin). These nuclei
were sonicated 3 times for 20 seconds at an output of 1
using a probe sonicator prior to PI hydrolysis assay.
Northern blot, PCR and tissue array analysis
Northern hybridization was carried out to detect the
expression of PLCδ4 mRNA in different normal tissues.
Specifically, nylon membranes containing mRNA isolated
from various human tissues and tumor cell lines (Clon-
tech, Palo Alto, CA) and cDNAs derived from various
matched tumor and normal tissues on Cancer Profiling
Array I and II (Clontech, Palo Alto, CA) were hybridized
in ULTRAhyb™ (Ambion, Austin, TX) with PLCδ4 (2000
bp Nhe I-Bgl II fragment from pPuroD4F) coding region
cDNA fragment labeled with [α-32P]dCTP using a Strip-Ez
labeling kit (Ambion, Austin, TX). To evaluate the relative
abundance of full length PLCδ4 and splice variant
PLCδ4b, primers, oD4_2f, 5'-AGACACGTCC CAGTCT-
GGAA CC-3', and oD4_2r, 5'-CTGCTTCCTC TTCCT-
CATAT TC-3', located upstream and downstream of the
coding region for exons 7, 8, and 9 were used to detect
PCR products in a Rapid-Scan™ Gene Expression Panel
(OriGene, Rockville, MD) generated from cDNA samples
derived from various normal human tissues. The full
length PLCδ4 would generate a 800 bp product; whereas
the splice variant PLCδ4b with exons 7, 8, and 9 deleted,
a 300 bp product.
Preparation of siRNAs and transfections
Several siRNAs targeting PLC-δ4 (accession number
BC006355) were synthesized by Dharmacon Research
(Lafayette, CO). siRNAs were annealed essentially as
described [41]. The sense strands for each siRNA duplex
were as follows. PLC-δ4 specific siRNA #1 beginning at nt
1612, 5'-GAGCAGAACCTTCAGAATAdTdT-3', #2 begin-
ning at nt 457, 5'-GAGCAGGGCTTCACCATTGdTdT-3',
#3 beginning at nt, 765, 5'-GGAAGGAGAAGAATTCG-
TAdTdT-3', #4 beginning at nt 1752, 5'-GATATCATCTT-
TCTCTGAAdTdT-3' and "Smart Pool" siRNAs which
combined the above PLC-δ4 siRNAs #1–4. The following
siRNAs were obtained from Dharmacon Research (sense
strands); Lamin A/C 5'-CUGGACUUCCAGAA-
GAACAdTdT-3' and Non-specific Control I 5'-NNAT-
GAACGTGAATTGCTCAA-3'. Human MCF7-PLCd4c16
breast cancer cells were grown in RPMI1640, supple-
mented with 10% fetal bovine serum. Cells were seeded at
60,000 cells/well in a six-well dish. These seed density
resulted in 15% confluency and was optimal for
transfection efficiencies and growth by 72 hrs. Cells were
transfected with 27 nM siRNA in serum free Opti-MEM I
using Oligofectamine (Invitrogen, Carlsbad, California).
Following 4 hr incubation with siRNAs, fetal bovine
serum to 2% v/v final was added. Cells were harvested and
extracts prepared for Western analysis 72 hr after
transfection.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/15
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